Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 5 days ago

Stoke Therapeutics, Inc.: MORGAN STANLEY amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 13 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Morgan Stanley amended its Schedule 13G filing for Stoke Therapeutics, disclosing a revised passive stake in the company via SEC accession 0000895421-26-000321. The filing updates the bank's previously reported ownership position in the clinical-stage RNA medicines developer, though the amended document did not specify a change in share count or percentage in the headline disclosure. Investors monitor 13G amendments for signals about shifts in institutional ownership, which can influence liquidity and sentiment in small-cap biotech names like Stoke. The next catalyst to watch is Stoke's own disclosure of its updated share count and any further institutional filings that clarify Morgan Stanley's current holding.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Morgan Stanley (MS), Stoke Therapeutics, Inc.

A linked name opens that asset's sentiment page.